

Horizons in Clinical Nanomedicine





edited by Varvara Karagkiozaki Stergios Logothetidis



Horizons in Clinical Nanomedicine

edited by
Varvara Karagkiozaki
Stergios Logothetidis



TORRETT

Published by

Pan Stanford Publishing Pte. Ltd. Penthouse Level, Suntec Tower 3 8 Temasek Boulevard Singapore 038988

Email: editorial@panstanford.com Web: www.panstanford.com

British Library Cataloguing-in-Publication Data

A catalogue record for this book is available from the British Library.

Horizons in Clinical Nanomedicine

Copyright © 2015 by Pan Stanford Publishing Pte. Ltd.


All rights reserved. This book, or parts thereof, may not be reproduced in any form or by any means, electronic or mechanical, including photocopying, recording or any information storage and retrieval system now known or to be invented, without written permission from the publisher.

For photocopying of material in this volume, please pay a copying fee through the Copyright Clearance Center, Inc., 222 Rosewood Drive, Danvers, MA 01923, USA. In this case permission to photocopy is not required from the publisher.

ISBN 978-981-4411-56-1 (Hardcover) ISBN 978-981-4411-57-8 (eBook)

Printed in the USA

Horizons in Clinical Nanomedicine



Preface

Nanomedicine, a flourishing field of medical research, is expected to provide modern medicine with innovative solutions to the unmet and unsolved clinical needs. Nanostructured materials have the potential to revolutionize healthcare, due to their novel intrinsic physicochemical properties which can be exploited towards cutting-edge developments in the fields of diagnosing, treating, and preventing diseases, injuries, or genetic disorders. Thus, clinical nanomedicine holds great promise as a future powerful tool of medicine that improves human health.

This book presents a broad overview on nanomedicine tools, materials, and processes to be applied to different medical disciplines. It presents the broad spectrum of nanomedicines for the early, accurate diagnosis and effective treatment of human diseases. Taking into account the pillars of in vitro and in vivo nanodiagnostics, regenerative medicine, and nanopharmaceuticals, it deals with the unsolved medical problems in cardiovascular disease, AIDS, cancer, blood diseases, congenital defects, dermatology, dentistry, and orthopaedics, with a focus on personalized medicine. It addresses nanosafety and nanotoxicity issues to highlight the significance of nanomedicine applied into clinical practice for the benefit of the patient. The book will appeal to researchers, medical doctors, and graduate students who want to get in-depth knowledge of nanomedicine utilities for clinical applications.



Contents

Pref	ace			xiii
1.	Introd	uction ir	n Clinical Nanomedicine	1
	Stergie	os Logot	hetidis	
	1.1	Introd	uction	2
	1.2	Nanon	nedicine and Diversity of Nanocarriers	5
	1.3		nedicine in Regenerative Medicine	9
	1.4	Nanon	nedicine in the Early Diagnosis of Diseases	12
		1.4.1	In vitro Diagnostics	13
		1.4.2	In vivo Diagnostics	18
	1.5	Target	ed Drug Delivery	21
		1.5.1	Nanocarrier-Based Drug Delivery	
			Systems	21
		1.5.2	Clinical Applications for	
			Nanocarrier-Based Drug Delivery	23
		1.5.3	Drug Targeting Approaches	26
	1.6		oxicology and Safety Aspects	28
	1.7	Conclu	isions	29
2.	Nanor	nedicine	Combats Atherosclerosis	39
	Varva	ra Karag	gkiozaki	
	2.1	Introd	uction	39
	2.2	Under	standing of Atherosclerosis	41
	2.3		nedicine for Accurate Diagnosis of	
		Athero	osclerosis	44
	2.4	Nanon	nedicine in Atherosclerosis Treatment	51
		2.4.1	Therapeutic Nanoparticles	51
		2.4.2	Nanomedicine for Stents	53
	2.5	Conclu	usions and Future Perspectives	56
3	. Nanoi	medicine	Advancements in Cancer Diagnosis and	
	Treatr	nent		67
	Eric N	1ichael E	Bratsolias Brown	
	3.1 Introduction			

	3.2		Properties of Gold, Iron oxide, and	
			ım Dioxide Nanoparticles That Benefit	
	0.0		Applications	69
	3.3		Gold, Iron Oxide, and Titanium Dioxide	
		75	articles in Cancer Diagnosis	71
	3.4		Gold, Iron Oxide, and Titanium Dioxide	
			articles in Cancer Therapy	75
	3.5		pment of Gold, Iron Oxide, and Titanium	
			e Nanoparticles for Cancer Theranostics	78
	3.6	Conclu	ision	79
4.	Nanon	nedicine	and Blood Diseases	93
	Emma	nouil Ni	kolousis	
	4.1	Introd	uction: Haematological Malignancy	
		Outcor		93
		4.1.1	Acute Myeloid Leukaemia Outcomes	94
	4.2	Major	Achievements in Haematology over	
		the Las	st Decade	97
		4.2.1	Targeted Therapy for Chronic Myeloid	
			Leukaemia	97
		4.2.2	Immunotherapy for Non-Hodgkin	
			Lymphoma	98
	4.3	Nanote	echnology and Its Use in Haematology:	
		Backgr		99
		4.3.1	Passive Targeting	101
		4.3.2	Active Targeting	101
		4.3.3	Destruction from Within	101
	4.4	Nanote	echnology and Diagnosis for	
		Haema	atological Diseases	102
	4.5	Nanotechnology in Specific Haematological		
		Cancer	rs	103
		4.5.1	Mantle Cell Lymphoma	103
		4.5.2	CNS Lymphomas	105
		4.5.3	Acute Leukaemias	106
		4.5.4	Chronic Myeloid Leukaemia	107
		4.5.5	Multiple Myeloma	108
	4.6	Major	Challenges Facing the Use of	
		Nanote	echnology in Haematology	109
	4.7	Conclu	ision	110

Contents	vii
----------	-----

5.	Nanom	edicine	and Orthopaedics	115		
	Fares E. Sayegh					
	5.1	Introdu	uction	115		
	5.2	The Ro	le of Nanomedicine in Early Screening			
		of Orth	opaedic Diseases	117		
	5.3	Nano E	Biologically Active materials and			
			vative Treatment of Early OA	117		
	5.4		echnology and Nanobiomaterials in			
			eatment of Advanced OA	118		
	5.5		Engineering in Orthopaedics	121		
	5.6	Conclu	sion	123		
6.	Nanop	harmace	eutics: Structural Design of Cationic			
	-	Gemini Surfactant-Phospholipid-DNA Nanoparticles				
	for Gene Delivery					
	for Gene Delivery Marianna Foldvari					
	6.1	Introdu	uction	130		
	6.2	Gemin	i Nanoparticles	133		
	6.3		article Structure Analysis	135		
	6.4	Nanop	article Structural Responsiveness and			
		Transfe	ection Efficiency	136		
	6.5	Conclu	isions	138		
7	Nanon	nedicine	and Embryology: Causative Embryotoxic			
			Can Pass the Placenta Barrier and Induce			
	Birth D			147		
	Elpida-Niki Emmanouil-Nikoloussi					
	7.1	Introd	uction	147		
	7.2	Drugs,	Environmental Pollution and			
			rotoxicity	150		
	7.3	Drugs,	Nanoparticles and Embryology	160		
		7.3.1	Causative Embryotoxic Agents			
			Inducing Cellular Apoptosis and			
			Creating Birth Defects	162		
		7.3.2	Embryonic Development and			
			Nanomolecules	162		
		7.3.3	Mechanics and Nanomolecules			
			during Development	163		

		7.3.4	Nanoparticles as a Study Tool in Developmental Processes and	2.212			
		DI	Reproductive Toxicology	164			
	7.4		ta Permeability and Nanoparticles	166			
	7.5	Conclu	ISIONS	167			
8.	Nanon	nedicine	and HIV/AIDS	175			
	Enikő l	R. Tőke d	and Julianna Lisziewicz				
	8.1	Introd	uction	175			
	8.2	Nanon	nedicine in Antiretroviral Drug				
		Develo	pment	177			
	8.3	Nanon	nedicine in Vaccine Development	179			
	8.4	Derma	DermaVir Clinical Nanomedicine Product				
		Candid	late for HIV Immunotherapy	182			
	8.5	Conclu	sion	188			
9.	Nanos	caffolds	and Other Nano-Architectures for				
	Tissue Engineering–Related Applications						
	Paraskevi Kavatzikidou and Stergios Logothetidis						
	9.1	Introduction					
	9.2	Nano-A	no-Architectures and Nanoscaffolds				
		9.2.1	Materials	196			
			9.2.1.1 Natural materials	197			
			9.2.1.2 Synthetic materials	197			
			9.2.1.3 Semi-synthetic materials	198			
		9.2.2	Fabrication Methods	199			
			9.2.2.1 Electrospinning	199			
			9.2.2.2 Self-assembly	200			
			9.2.2.3 Phase separation	201			
		9.2.3	Different Architectures and Their				
			Properties	201			
	9.3	Tissue	Engineering	202			
		9.3.1	Introduction	202			
		9.3.2	Material Requirements	203			
		9.3.3	Fabrication Methods	203			
	9.4	Bone a	and Cartilage Engineering Applications	206			
		9.4.1	Bone Biology	206			
		9.4.2	Bone-Related Clinical Problems	207			
		9.4.3	Bone-Related Applications	208			

		9.4.4 Nanom	aterials for Cartilage				
		Applica	itions	210			
	9.5	Cardiac Engine	ering Applications	211			
	9.6	Nerve Enginee	ring Applications	212			
	9.7	Correlation of	Cell–Material Interactions				
		at the Nanosca	le	215			
	9.8	Conclusions		218			
10.			3D Polymeric Scaffolds for				
	Medica	l Devices		229			
	Masarı	ı Tanaka					
	10.1	Introduction: A	an Explanation of the Design				
		and Research	on Polymeric Biomaterials	230			
	10.2	Biocompatible		230			
	10.3		tion on Polymer Surfaces	232			
	10.4	Water Structur	e and Dynamics of Polymer	234			
	10.5		Scaffolds for Tissue Engineering	237			
	10.6	Methods of 3D	Scaffold Fabrication	238			
			wn Fabrication	238			
			ı-Up Fabrication	238			
	10.7	Control of Cell	Adhesion and Functions	244			
	10.8	Conclusions ar	d Perspectives	246			
11.	Regene	Regenerative Dentistry: Stem Cells meet Nanotechnology 255					
	Nanotechnology						
	Lucía Jiménez-Rojo, Zoraide Granchi, Anna Woloszyk,						
	Anna F	ilatova, Pierfrai	ncesco Pagella, and				
	Thimic	s A. Mitsiadis					
	11.1	Introduction		255			
	11.2	Dental Stem Co	ells	256			
		11.2.1 Dental	Mesenchymal Stem Cells	257			
		11.2.1	1 Dental pulp stem cells	257			
		11.2.1	2 Stem cells from human				
			exfoliated deciduous teeth	258			
		11.2.1	3 Stem cells from the apical				
			part of the papilla	259			
		11.2.1	4 Periodontal ligament stem				
			cells	260			
		11.2.1	5 Stem cells from the dental				
			follicle	260			

		11.2.2	Dental E	pitheliai Stem Cells	261
			11.2.2.1	Epithelial stem cells in	
				rodent incisors	261
			11.2.2.2	Epithelial stem cells in	
				human teeth	263
	11.3	Regene	rative De	ntistry	264
		11.3.1	Approac	hes for Tooth Regeneration	265
			11.3.1.1	Regeneration of the pulp	
				/dentin complex	266
			11.3.1.2	Regeneration of periodontal	
				tissues	267
			11.3.1.3	Regeneration of enamel	268
			11.3.1.4	Regeneration of an entire	
				tooth	268
			11.3.1.5	Challenges of dental tissue	
				regeneration	270
	11.4	Stem C	ells Meet	Nanotechnology	271
		11.4.1		p of Stem Cells after	
			Transpla		272
				Magnetic nanoparticles	272
				Quantum dots	273
		11.4.2		otein and Drug Intracellular	
			Delivery		273
		11.4.3	Nanobio		274
			11.4.3.1	Nanotechnology for the	
				design of artificial stem cell	
				niches	274
				Design of nanofiber scaffolds	275
	11.5	Conclu	sions		276
12	Tovicity	, and Go	notovicity	of Metal and Metal Oxide	
12.				al Introduction	289
				z, and Sergio E. Moya	203
				z, una Sergio E. Moya	200
	12.1	Introdu		+M-+11M-+10-11-	289
	12.2			nt Metal and Metal Oxide	202
		-		n the Immune Response	292
				n Dioxide Nanoparticles	292
				de Nanoparticles	292
				de Nanoparticles	294
		12.2.4	cerium (Oxide Nanoparticles	297

13.3.1.1 Diesel exhaust particles

328

		13.3.1.2	Carbon black	330
		13.3.1.3	Role of contaminants in	
			the immune reaction to	
			diesel exhaust particles	331
	13.4	Medical Nanopa	rticles	332
		13.4.1 Use of N	on-Biodegradable	
		Nanopar	rticles in Medicine	332
		13.4.2 Immuno	toxicity and Effects of	
		Medical	Nanoparticles on the	
		Immune	System	332
		13.4.2.1	Iron oxide nanoparticles	333
		13.4.2.2	Gold nanoparticles	333
		13.4.2.3	Silver nanoparticles	333
		13.4.2.4	Silica nanoparticles	334
		13.4.2.5	Carbon nanotubes	334
		13.4.2.6	Size-dependency of the	
			immune effects	335
		13.4.2.7	Comparison of immune	
			effects of different particles	335
	13.5	Conclusions		338
nde	X			349

Chapter 1

Introduction in Clinical Nanomedicine

Stergios Logothetidis

Lab for Thin Films—Nanosystems and Nanometrology, Department of Physics, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece logot@auth.gr

Nanotechnology represents the possibility of revolutionising many aspects of our lives. Nanomedicine, the application of nanotechnology to health, is one of the most promising fields of biomedical research, building up a novel research culture by encompassing the principles of traditional disciplinary boundaries (i.e., physics, chemistry, biology and engineering). Nanomedicine has the potential to give intelligent solutions to many of the current medical problems, by opening the door to a new generation of advanced drug delivery systems, improved diagnostic systems (in vitro and in vivo) and novel methods and materials for regenerative medicine. There are currently two families of therapeutic nanocarriers (i.e., liposomes and albumin nanoparticles) that have been approved and used in clinical settings, providing clinical benefit. Moreover, several nanocarriers are in clinical trials and even more are in pre-clinical

phases. Despite the cutting-edge developments in nanomedicine, the process of converting basic research to viable products is expected to be long and ambitious. A crucial factor that should also be taken into consideration is the toxic effects of the novel therapeutical products in human health. Thus, a massive effort is required to translate laboratory innovation to the clinic and begin to change the landscape of medicine.

1.1 Introduction

Richard Feynman in 1959^1 was the first one to claim that 'there is plenty of room at the bottom', and since then, a booming interest in studying the nanoscale has emerged. The nano prefix comes from the Greek word 'Nano' meaning dwarf, with 1 nanometre (nm) being equal to one billionth of a metre $(10^{-9} \, \text{m})$, or 10 water molecules, or about the width of six carbon atoms. Atoms are smaller than 1 nm, whereas many molecules, including proteins, can range in size from 1 nm to several hundreds, as shown in Fig. $1.1.^2$ Studying at such scales is of great importance, as the properties of matter differ significantly, especially due to quantum effects and the large surface-to-volume atom ratio. As a result, new findings arise, contributing to a better understanding of science.




Figure 1.1 Nanoworld and Macroworld: the scale of natural objects.³